Tara’s family funds all event and foundation costs so that every dollar raised goes directly to research and is 100% tax deductible.
YOU ARE CORDIALLY INVITED TO CELEBRATE OUR

6TH ANNUAL

Make The Best Of It Bash

Honoring Tara’s legacy and celebrating 6 years of “Making The Best Of It” by funding research for a cure.

Friday, June 28, 2019
7:00 pm to 10:00 pm
Atlantic City, NJ

ENJOY AN EVENING OF SPECTACULAR

Cocktails & Hors D’Oeuvres
AMAZING SILENT AUCTION & AFTER PARTY

EVERY DOLLAR IN GOES OUT!
Tara’s family funds all event and foundation costs so that every dollar raised goes directly to research and is 100% tax deductible.

Ticket & Sponsorship Information Enclosed
You can also purchase sponsorships, buy tickets, book discounted hotel rooms and learn more at TaraMillerFoundation.org

TaraMillerFoundation.org
PRESENTING SPONSORSHIP AVAILABLE UPON REQUEST

☐ DIAMOND SPONSOR $25,000
- 10 Sponsor Tickets
- Website Recognition
- Social Media Recognition
- Logo on Screens & Included in Signage at Event
- Included in Eblast
- Included in Radio Spot
- Included in Press Release
- Logo on Step & Repeat
- Verbal Recognition at Event
- Logo on Advertisements
- Program Book Inside Cover (8"x10.5")

☐ PLATINUM SPONSOR $15,000
- 10 Sponsor Tickets
- Website Recognition
- Logo on Screens & Included in Signage at Event
- Full Pg. Program Book Ad (8"x10.5")

☐ GOLD SPONSOR $10,000
- 10 Sponsor Tickets
- Website Recognition
- Logo on Screens at Event
- Full Pg. Program Book Ad (8"x10.5")

☐ SILVER SPONSOR $5,000
- 10 Sponsor Tickets
- Website Recognition
- Logo on Screens at Event
- Full Pg. Program Book Ad (8"x10.5")

☐ BRONZE SPONSOR $2,500
- 10 Sponsor Tickets
- Website Recognition
- Logo on Screens at Event
- Full Pg. Program Book Ad (8"x10.5")

Please submit all logos for sponsorship packets to info@taramillerfoundation.org.

☐ Yes, I would like to be a_________ sponsor, enclosed is my check for__________.

☐ Yes, I can attend, please reserve______ seat(s) at $150 per person.

☐ No, I am unable to attend. Please accept my donation of $___________.

Contact Name _____________________________
Sponsor/Supporter Name ___________________________
Address _________________________________________
City ______________________ State/Zip ____________
Telephone __________________________ Email ___________________________
Amount Enclosed $ _______________________

Please provide the wording for how you would like your sponsorship listed.

MAKE CHECK PAYABLE TO: Tara Miller Melanoma Foundation
SEND CHECK TO: Tara Miller Melanoma Foundation
Po Box 3154, Margate, NJ 08402
For questions and information email taramillerfoundation@gmail.com

EVERY DOLLAR IN GOES OUT!
Tara’s family funds all event and foundation costs so that every dollar raised goes directly to research and is 100% tax deductible.
In July 2013, Tara Miller Esq. was diagnosed with advanced melanoma at the age of 28. In the face of insurmountable odds, her love for life and having fun was unwavering; she was determined to “Make The Best Of It.” Known for her quick-witted sense of humor, Tara often wore her trademark funny t-shirts to treatments including favorites like, “More Issues than Vogue” and “Not My First Rodeo.”

Her determination to find the #Silverlining in every aspect of her life, including the fight for her life, is how the Tara Miller Foundation was born. She realized this cancer’s devastating odds and lack of effective treatment options. She started this foundation in 2014 with the intent that her path might forge a better, more hopeful future for melanoma patients even though she knew it likely wouldn’t change hers.

Tara passed away on October 14, 2014; only a few months after the first Make the Best Of It Bash and 6 weeks before her 30th birthday. Her desire to #Makethebestofit not just for her but for future melanoma patients lives on through this Foundation. Tara’s relentless positivity and tenacious spirit resonated with everyone lucky enough to have known her. The Make The Best Of It Bash is the combination of Tara’s love of a party and a vehement wish to fund melanoma research and find a cure.

“According to statistics, 75% of Stage 4 melanoma patients like myself are dead within a year of their diagnosis - I was diagnosed 11 months ago and even after having somewhere around 14 brain tumors - yes I lost count - I know that those aren’t good odds. I can’t control those statistics, but part of making the best of it is accepting what I can’t control and focusing on what I can control. So, although we can’t change what the statistics on melanoma have been, we choose to Make The Best Of It and try to help change where they are going.

- Tara Miller (June 2014).
When Tara decided to start this foundation and set off planning the first event she was very clear on what she wanted. First and foremost, she wanted it to be a successful event that raised money for melanoma research. But it was also very important to her that the event be a fun night for everyone who attends. She wanted a fun cocktail party where people can mingle and a great auction for people to shop for a cause.

The first Make The Best Of It Bash was held in June 2014. On that night, Tara inspired everyone who heard her courage, wit and even humor as she spoke about why this foundation was so important to her. Tara tragically lost her battle 5 months after that first event. However, she made it very clear that she wanted us all to continue her fight for a cure, no matter her outcome.

The Make The Best Of It Bash continues to honor Tara's vision for what a fun event should be along with her passion for raising money to find a cure. In 2017, some of the auction highlights include dinners with Charles Barkley and Connor Barwin, Bruce Springsteen tickets with a meet and greet with the E Street Band, vacations and cruises, jewelry and so much more.

*The Tara Miller Melanoma Foundation is only possible because of the tremendous community support and dedication to carrying on Tara’s mission to #makethebestofit and push for a Melanoma cure.*

Please join us Friday, June 28, 2019 for a fun night of “Making The Best Of It” and honoring Tara’s incredible legacy!

**EVERY DOLLAR IN GOES OUT!**
Tara’s family funds all event and foundation costs so that every dollar raised goes directly to research and is 100% tax deductible.
Impact & Breakthroughs
FROM RESEARCH FUNDED BY THE TARA MILLER MELENOMA FOUNDATION

In 2014, Tara described her wish for this foundation...

"What I really want to do with this foundation is to help fund the research that will get us past just buying time and will hopefully provide a lifetime to melanoma patients." — Tara Miller

Earlier this year, research that TMMF has funded since 2014 was published in Nature Magazine and as a result it will immediately impact how physicians make treatment decisions for their patients. The study done at Penn’s Abramson Cancer Center demonstrates whether or not a patient is responding to PD-1 blockade (Keytruda) as early as 7 days after one dose of treatment. Learnings show that one dose of PD1 before surgery might stop the cancer in its tracks. A portion of patients saw complete response (for over 2 years). Researchers also found revealing patterns in the way cancer adapts to the drug -- discoveries that could lead to better ways to treat those patients, patients like Tara who are in the group that do not respond to PD1. Not only has TMMF supported each phase of this study since 2014 (and also provided the seed funding early on to get a government grant) but Tara’s actual tissue samples were also used in the study.

In 2014, only about 20% of patients responded to treatments...
Because of research breakthroughs, 4 new therapies have been FDA approved...
In 2018, about 50% of patients are responding to treatments and combination therapies that are now available because of research breakthroughs...

"In the past 5 years, philanthropic funding has allowed us to make breakthroughs, discover new treatment options and changed the way we approach this disease - we are truly improving the odds for patients." — Dr. Lynn Schuchter (March 2019)

OVER $3.1 MILLION FUNDED TO MELANOMA RESEARCH
100% OF ALL FUNDS GO TO RESEARCH. NO ADMIN OR OVERHEAD

24 PROJECTS SELECTED & FUNDED IN COLLABORATION WITH LEADERS IN THE FIELD
Funded Projects at 5 of the Top Institutes for Melanoma Research in the World
7 High Impact Studies Published as a Result of These Funds

24 PROJECTS

5

7

THIS FUNDING IS BRINGING TARA’S MISSION WITHIN REACH WITH TANGIBLE, LIFE CHANGING RESULTS THAT WILL IMPROVE THE OUTCOME FOR PATIENTS

TaraMillerFoundation.org
2019 Research Funded Update

I am on drugs that were not available a year ago. Hopefully one day we will get to see the money raised by this Foundation making a difference in someone else’s fight against this terrible disease.

— Tara Miller, (June 2014)

$3,134,000 FUNDED TO MELANOMA RESEARCH

$900,000 Funded to Melanoma Research Alliance Young Investigators
as part of Team Science Awards that foster collaboration across the field

<table>
<thead>
<tr>
<th>Institution</th>
<th>Amount</th>
<th>Project Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Penn &amp; Wistar Institute</td>
<td>$225,000</td>
<td>For a study looking at radiation &amp; immune checkpoint blockade from mechanism to patients</td>
</tr>
<tr>
<td>Tel-Aviv University &amp; Dana-Farber</td>
<td>$225,000</td>
<td>For a study looking at novel regulators of melanoma brain metastasis</td>
</tr>
<tr>
<td>MD Anderson</td>
<td>$225,000</td>
<td>For a study analyzing how chemical modifications to DNA can result in resistance to immunotherapies</td>
</tr>
<tr>
<td>UC San Francisco</td>
<td>$225,000</td>
<td>For a study looking at genetic mutations to better understand initiation &amp; progression</td>
</tr>
</tbody>
</table>

$2,234,000 FUNDED TO MELANOMA RESEARCH

at Penn’s Abramson Cancer Center Melanoma Program

<table>
<thead>
<tr>
<th>Year</th>
<th>Amount</th>
<th>Project Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>$334,000</td>
<td>Melanoma Immunotherapy&lt;br&gt;Effects of Age on Melanoma Outcomes&lt;br&gt;Phase I RadVax Trial&lt;br&gt;Melanoma CAR T Cell Trial&lt;br&gt;Melanoma Brain Metastasis&lt;br&gt;Role of Estrogen in Moles Becoming Melanoma&lt;br&gt;Melanoma Resistance to Targeted Therapies&lt;br&gt;Novel Approach to T Cell Therapy in Melanoma&lt;br&gt;RadVax in Melanoma with Triple Therapy&lt;br&gt;Innovative Melanoma Research Fund&lt;br&gt;Overcoming Resistance to Melanoma Immunotherapy&lt;br&gt;Understanding Melanoma Metastasis&lt;br&gt;Who Benefits from Melanoma Immunotherapy&lt;br&gt;Melanoma Resistance to Targeted Therapies (Year 2)&lt;br&gt;Estrogen and Sensitivity to Melanoma Immunotherapy (Year 2)&lt;br&gt;PD-1 Biomarker Evaluation&lt;br&gt;Anti-CTLA in Melanoma Treatment&lt;br&gt;Innovative Melanoma Research Fund&lt;br&gt;Deciphering Potential Clues from Melanoma Tumors&lt;br&gt;Innovations in Immune Monitoring&lt;br&gt;Copper as a New Approach to Melanoma Treatment&lt;br&gt;Who Benefits from Melanoma Immunotherapy&lt;br&gt;Starting Out Strong with PD-1 Blockade&lt;br&gt;PD-1 Biomarker Evaluation&lt;br&gt;Liquid Biopsy Initiative&lt;br&gt;Innovative Melanoma Research Fund</td>
</tr>
<tr>
<td>2015</td>
<td>$400,000</td>
<td>DNA Vaccine Strategy&lt;br&gt;Melanoma Brain Metastasis&lt;br&gt;Role of Estrogen in Moles Becoming Melanoma&lt;br&gt;Melanoma Resistance to Targeted Therapies&lt;br&gt;Novel Approach to T Cell Therapy in Melanoma&lt;br&gt;RadVax in Melanoma with Triple Therapy&lt;br&gt;Innovative Melanoma Research Fund&lt;br&gt;Overcoming Resistance to Melanoma Immunotherapy&lt;br&gt;Understanding Melanoma Metastasis&lt;br&gt;Who Benefits from Melanoma Immunotherapy&lt;br&gt;Melanoma Resistance to Targeted Therapies (Year 2)&lt;br&gt;Estrogen and Sensitivity to Melanoma Immunotherapy (Year 2)&lt;br&gt;PD-1 Biomarker Evaluation&lt;br&gt;Anti-CTLA in Melanoma Treatment&lt;br&gt;Innovative Melanoma Research Fund&lt;br&gt;Deciphering Potential Clues from Melanoma Tumors&lt;br&gt;Innovations in Immune Monitoring&lt;br&gt;Copper as a New Approach to Melanoma Treatment&lt;br&gt;Who Benefits from Melanoma Immunotherapy&lt;br&gt;Starting Out Strong with PD-1 Blockade&lt;br&gt;PD-1 Biomarker Evaluation&lt;br&gt;Liquid Biopsy Initiative&lt;br&gt;Innovative Melanoma Research Fund</td>
</tr>
<tr>
<td>2016</td>
<td>$450,000</td>
<td>DNA Vaccine Strategy&lt;br&gt;Melanoma Brain Metastasis&lt;br&gt;Role of Estrogen in Moles Becoming Melanoma&lt;br&gt;Melanoma Resistance to Targeted Therapies&lt;br&gt;Novel Approach to T Cell Therapy in Melanoma&lt;br&gt;RadVax in Melanoma with Triple Therapy&lt;br&gt;Innovative Melanoma Research Fund&lt;br&gt;Overcoming Resistance to Melanoma Immunotherapy&lt;br&gt;Understanding Melanoma Metastasis&lt;br&gt;Who Benefits from Melanoma Immunotherapy&lt;br&gt;Melanoma Resistance to Targeted Therapies (Year 2)&lt;br&gt;Estrogen and Sensitivity to Melanoma Immunotherapy (Year 2)&lt;br&gt;PD-1 Biomarker Evaluation&lt;br&gt;Anti-CTLA in Melanoma Treatment&lt;br&gt;Innovative Melanoma Research Fund&lt;br&gt;Deciphering Potential Clues from Melanoma Tumors&lt;br&gt;Innovations in Immune Monitoring&lt;br&gt;Copper as a New Approach to Melanoma Treatment&lt;br&gt;Who Benefits from Melanoma Immunotherapy&lt;br&gt;Starting Out Strong with PD-1 Blockade&lt;br&gt;PD-1 Biomarker Evaluation&lt;br&gt;Liquid Biopsy Initiative&lt;br&gt;Innovative Melanoma Research Fund</td>
</tr>
<tr>
<td>2017</td>
<td>$500,000</td>
<td>DNA Vaccine Strategy&lt;br&gt;Melanoma Brain Metastasis&lt;br&gt;Role of Estrogen in Moles Becoming Melanoma&lt;br&gt;Melanoma Resistance to Targeted Therapies (Year 2)&lt;br&gt;Estrogen and Sensitivity to Melanoma Immunotherapy (Year 2)&lt;br&gt;PD-1 Biomarker Evaluation&lt;br&gt;Anti-CTLA in Melanoma Treatment&lt;br&gt;Innovative Melanoma Research Fund&lt;br&gt;Deciphering Potential Clues from Melanoma Tumors&lt;br&gt;Innovations in Immune Monitoring&lt;br&gt;Copper as a New Approach to Melanoma Treatment&lt;br&gt;Who Benefits from Melanoma Immunotherapy&lt;br&gt;Starting Out Strong with PD-1 Blockade&lt;br&gt;PD-1 Biomarker Evaluation&lt;br&gt;Liquid Biopsy Initiative&lt;br&gt;Innovative Melanoma Research Fund</td>
</tr>
<tr>
<td>2018</td>
<td>$550,000</td>
<td>DNA Vaccine Strategy&lt;br&gt;Melanoma Brain Metastasis&lt;br&gt;Role of Estrogen in Moles Becoming Melanoma&lt;br&gt;Melanoma Resistance to Targeted Therapies (Year 2)&lt;br&gt;Estrogen and Sensitivity to Melanoma Immunotherapy (Year 2)&lt;br&gt;PD-1 Biomarker Evaluation&lt;br&gt;Anti-CTLA in Melanoma Treatment&lt;br&gt;Innovative Melanoma Research Fund&lt;br&gt;Deciphering Potential Clues from Melanoma Tumors&lt;br&gt;Innovations in Immune Monitoring&lt;br&gt;Copper as a New Approach to Melanoma Treatment&lt;br&gt;Who Benefits from Melanoma Immunotherapy&lt;br&gt;Starting Out Strong with PD-1 Blockade&lt;br&gt;PD-1 Biomarker Evaluation&lt;br&gt;Liquid Biopsy Initiative&lt;br&gt;Innovative Melanoma Research Fund</td>
</tr>
</tbody>
</table>

To learn more about the research or read the 2019 full annual report with updates, please visit taramillerfoundation.org